Abstract
Objective: Esomeprazole (ESO) is one of the proton-pump inhibitors and is used to treat gastroesophageal reflux. It is sensitive to low pH, heat,moisture, and oxidation, which often means that ESO in clinical samples is degraded at the time of storage, affecting analysis results. This study aimedto analyze the in vivo stability of ESO in subjects’ plasma samples by testing the incurred sample stability (ISS) of ESO in plasma following 7, 14, and28 days of storage at two concentrations close to Cmax and one concentration in the elimination phase.Methods: Samples were analyzed using high-performance liquid chromatography with a C18 column with detection at 300 nm using a photodiodearray detector. Lansoprazole was used as an internal standard.Results: The ESO pharmacokinetics profile in the plasma samples yielded the values of Cmax 704.57–1425.85 ng/mL; tmax is 2.25 h; and AUC0-t is2444 ng.h/mL. ISS testing of plasma samples values were 6.50%, 5.73%, and 4.57% on first Cmax concentration; 3.55%, 4.84%, and 3.68% on 2nd Cmaxconcentration; and 4.04%, 4.80%, and 4.98% on elimination phase concentration.Conclusion: ISS testing results of plasma samples from six healthy subjects who were administered doses of 40 mg of ESO stored for 28 days showedthat it fulfilled the acceptance criteria (<20%) of the 2011 EMEA Bioanalytical Guidelines with a %diff value in all incurred samples of 6.5%.
Highlights
Esomeprazole (ESO) is a proton-pump inhibitor (PPI) that is suggested for the reduction of symptoms in patients with gastroesophageal reflux disease [1,2]
ESO is the first single optical isomer PPI, derived from omeprazole, which provides better acid control than other racemic PPI and has favorable pharmacokinetic profile compared to omeprazole [3]
ESO magnesium trihydrate was purchased from Dr Reddy’s Laboratories Ltd. (Hyderabad, India); lansoprazole, which was used as an internal standard, was purchased from SigmaAldrich Pvt
Summary
Esomeprazole (ESO) is a proton-pump inhibitor (PPI) that is suggested for the reduction of symptoms in patients with gastroesophageal reflux disease [1,2]. ESO as PPI inhibits hydrogen-potassium adenosine triphosphatase in gastric parietal cells and blocks gastric acid secretion [1,2]. ESO is the first single optical isomer PPI, derived from omeprazole, which provides better acid control than other racemic PPI and has favorable pharmacokinetic profile compared to omeprazole [3]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
